Studying early immune changes in children with ITP and lupus
Part of Blood & lymphatic, Immune system & allergy, Skin clinical trials.
This study looks at how the immune system goes wrong at the very start of two autoimmune conditions in children: ITP (low blood platelets causing bruising) and lupus (which can affect skin, joints, and organs). Researchers will compare blood samples from patients and healthy children to find early signs of disease, with the goal of better understanding and treating these conditions.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Child or teen aged 1 to 17 who weighs more than 7 kg
- Newly diagnosed with immune thrombocytopenia (ITP) or lupus (SLE) and hasn't started treatment
- If an adult with a condition not affecting the immune system, can join as a control
- Parent or guardian must sign a consent form
- Must be covered by health insurance (social security)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood test antibodies to help confirm whether low platelet counts are caused by an autoimmune condition. It may help doctors better classify your type of low platelets and guide appropriate next steps.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study follows children aged 6-17 with immune thrombocytopenia (ITP) over time to better understand the condition and how it changes. It aims to learn more about ITP in children to improve future care.
This study looks at how a treatment called CD3xCD19 BiTE affects the immune system of children with lupus that hasn't gotten better with standard medicines. It uses leftover blood samples to learn more about why some children don't respond to usual treatments.
This trial studies whether a “dose-dense” rituximab schedule can help children and teens with newly diagnosed, high-risk immune thrombocytopenia (ITP). It aims to raise/maintain platelet counts and control bleeding, while carefully checking safety.
This study tests a new combination of two medicines (ianalumab and eltrombopag) for children with a blood condition called ITP (low platelets causing bruising and bleeding) who haven't improved with steroids. The goal is to see if this combination can safely raise platelet counts and reduce bleeding risk.
Hear when a new Immune Thrombocytopenic Purpura ( ITP ) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.